Spots Global Cancer Trial Database for Compassionate Use of BYL 719 Alpelisib
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Compassionate Use of BYL 719 Alpelisib
Official Title: INST UNM 1601: Compassionate Use of BYL 719 Alpelisib
Study ID: NCT03941782
Conditions
Interventions
Study Description
Brief Summary: This is a compassionate use protocol of BYL719 (alpelisib) treatment for a single patient with locally advanced lymphangioma positive PI3K alpha H1047R mutation.
Detailed Description: As a single agent, alpelisib will be administered at a starting dose of 350 mg orally once daily on a continuous dosing schedule and can be adjusted for toxicity per the recommendations in this protocol. No pretreatment will be given prior to the medication. We plan on treating this individual patient for a tentative period of 12 weeks at which time treating physician will reevaluate the patient's clinical and radiological response and further duration of treatment will be contingent on that assessment.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of New Mexico - Cancer Center, Albuquerque, New Mexico, United States
Contact Details
Name: Ian Rabinowitz, MD
Affiliation: University of New Mexico Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
